Single-dose WVE-007 reduced circulating Activin E by 56% at 75 mg, 75% at 240 mg, and 85% at 400 mg at day 29 in Wave Life Sciences’ INLIGHT trial (p<0.0001 for all doses). Reductions at the lowest dose were sustained through six months, and the program remains generally well tolerated to date. An independent data monitoring committee supported the expansion of a 600 mg cohort and further dose escalation. Wave’s core update is target engagement for WVE-007, a GalNAc-siRNA that silences INHBE for obesity with the aim of driving fat loss while preserving muscle. The company plans multiple data updates from INLIGHT beginning in 4Q 2025, including body composition and weight. Wave also advanced its hepatic RNA franchise: WVE-006 for alpha-1 antitrypsin deficiency has achieved serum AAT levels and protein restoration consistent with disease modification in an ongoing Phase 1b/2a, with 600 mg dosing underway; and WVE-008, an RNA editing candidate targeting PNPLA3-I148M liver disease, is slated for a 2026 CTA. Preclinical platform work highlighted extrahepatic delivery efforts and a single-construct approach that combines RNA editing and silencing. Strategically, Wave is positioning a low-frequency, liver-directed RNAi in an obesity market dominated by high-frequency incretin regimens. The biology is differentiated: reducing Activin E via INHBE knockdown is intended to shrink visceral fat while sparing lean mass, potentially as an add-on to GLP-1s or as a maintenance therapy post-GLP-1 cessation. The dose-dependent, durable biomarker reductions validate target engagement and support the once- or twice-yearly dosing thesis. The tension is clear, however: the readout is a biomarker signal without weight or body composition outcomes yet, and the company is explicitly setting a bar of semaglutide-comparable fat loss at six months post a single dose. Translating Activin E suppression into clinically meaningful, regulator-acceptable endpoints will determine whether this becomes a standalone or adjunct play. For sites and CROs, trial execution will likely hinge on long follow-up windows, retention, and standardized body composition assessments. Expect increased use of DEXA or MRI-based measures to quantify visceral fat alongside central labs for Activin E, glucose, and lipid panels. Low visit frequency for dosing can reduce site burden but shifts operational emphasis to remote monitoring, adherence tracking, and timely imaging logistics. Safety surveillance will focus on hepatic labs and immune activation signals typical of oligonucleotide programs. For sponsors and tech vendors, this is another nudge toward hybrid designs with sparse in-clinic dosing and heavy data collection between visits. Regulators will treat Activin E as supportive biology; decision-making will turn on percent total weight loss, visceral fat change, and cardiometabolic markers, as well as durability and safety over 6–12 months. Key watch items over the next 12–18 months are the initial body composition and weight data from the 240 mg cohort in 4Q 2025, six-month outcomes for 240 mg in 1Q 2026 and for 400 mg in 2Q 2026, and clarity on dose frequency. Look for signals on combination design with GLP-1s, hepatic safety at higher doses, and whether Wave pursues a maintenance-therapy positioning. Beyond obesity, the PNPLA3 program’s CTA in 2026 and the dual edit/silence construct raise CMC and regulatory questions around novel oligo architectures. If efficacy aligns with the biomarker signal, the development narrative shifts from novelty to scalability, including manufacturing capacity and global site footprint to run large metabolic outcomes trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Wave Life Sciences Advances WVE-007 to Phase 2a for Obesity and Metabolic Disease
3 weeks ago[…] Life Sciences entered Phase 2a of its INLIGHT trial with WVE-007 carrying Phase 1 data showing visceral fat reduction and muscle preservation on what could […]